Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study

Multiple Sclerosis

Volumn 21, Issue 6, 2015, Pages 767-775

  Achiron, Anat ^a   Givon, Uri ^a   Magalashvili, David ^a   Dolev, Mark ^a   Liraz Zaltzman, Sigal ^a   Kalron, Alon ^a   Stern, Yael ^a   Mazor, Zeev ^b   Ladkani, David ^b   Barak, Yoram ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Teva Pharmaceutical Industries ^*  (Israel)

Author keywords

Alfacalcidol; clinical trial; fatigue; Multiple sclerosis; Quality of Life

Indexed keywords

ALFACALCIDOL; METHYLPREDNISOLONE; PLACEBO; VITAMIN D DERIVATIVE; BONE DENSITY CONSERVATION AGENT; HYDROXYCOLECALCIFEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FATIGUE SEVERITY SCALE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; ISRAEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS RELATED FATIGUE; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGISTER; RELAPSE; SELF REPORT; SOCIAL ASPECT; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT; COMPLICATION; FATIGUE; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RECURRENCE; REGISTRIES; TREATMENT OUTCOME;

EID: 84930519241     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514554053     Document Type: Article

References (23)

1. Amato MP, Portaccio E. Management options in multiple sclerosis-associated fatigue. Expert Opin Pharmacother. 2012 ; 13: 207-216
2. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 ; 58: 169-178
3. Rubin SM. Management of cognition and fatigue. Dis Mon. 2013 ; 59: 269-272
4. Sheng P, Hou L, Wang X, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: A systematic review and meta-analysis. PLoS One. 2013 ; 8: e81802
5. Kargarfard M, Etemadifar M, Baker P, et al. Effect of aquatic exercise training on fatigue and health-related quality of life in patients with multiple sclerosis. Arch Phys Med Rehabil. 2012 ; 93: 1701-1708
6. Moss-Morris R, McCrone P, Yardley L, et al. A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue. Behav Res Ther. 2012 ; 50: 415-421
7. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004 ; 52: 230-236
8. Moran DS, McClung JP, Kohen T, et al. Vitamin D and physical performance. Sports Med. 2013 ; 43: 601-611
9. Schacht E. Reduction of falls and osteoporotic fractures: Plain vitamin D or D-hormone analogs?. Geriatr Gerontol Int. 2008 ; 8: S16 - S25
10. Farias AS, Spagnol GS, Bordeaux-Rego P, et al. Vitamin D3 induces IDO(+) tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci Ther. 2013 ; 19: 269-277
11. Achiron A, Barak Y, Miron S, et al. Alfacalcidol treatment in multiple sclerosis. Clin Neuropharmacol. 2003 ; 26: 53
12. Achiron A, Feldman A, Gurevich M. Characterization of multiple sclerosis traits: Nuclear receptors (NR) impaired apoptosis pathway and the role of 1-α 25-dihydroxyvitamin D3. J Neurol Sci. 2011 ; 311: 9-14
13. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 ; 46: 1121-1123
14. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
15. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994 ; 18: S79-83
16. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994 ; 21: 9-14
17. Rotstein Z, Barak Y, Noy S, et al. Quality of life in multiple sclerosis: Development and validation of the 'RAYS' scale and comparison with the SF-36. Int J Qual Health Care. 2000 ; 12: 511-517
18. Blaney GP, Albert PJ, Proal AD. Vitamin D metabolites as clinical markers in autoimmune and chronic disease. Ann N Y Acad Sci. 2009 ; 1173: 384-390
19. Svenningsson A, Falk E, Celius EG, et al. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One. 2013 ; 8: e58643
20. Etemadifar M, Sayahi F, Abtahi SH, et al. Ginseng in the treatment of fatigue in multiple sclerosis: A randomized, placebo-controlled, double-blind pilot study. Int J Neurosci. 2013 ; 123: 480-486
21. Dayapolu N, Tan M. Evaluation of the effect of progressive relaxation exercises on fatigue and sleep quality in patients with multiple sclerosis. J Altern Complement Med. 2012 ; 18: 983-987
22. Wergeland S, Torkildsen O, Myhr KM, et al. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS One. 2011 ; 6: e26262
23. Berkovitz S, Ambler G, Jenkins M, et al. Serum 25-hydroxy vitamin D levels in chronic fatigue syndrome: A retrospective survey. Int J Vitam Nutr Res. 2009 ; 79: 250-254